Phathom Pharmaceuticals (PHAT) Retained Earnings (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Retained Earnings data on file, last reported at -$1.5 billion in Q1 2026.

• Retained Earnings for Q1 2026 came in at -$1.5 billion, down 11.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.5 billion (down 11.59% YoY), and the FY2025 annual result was -$1.5 billion, down 17.52% from the prior year.
• Retained Earnings fell to -$1.5 billion in Q1 2026 per PHAT's latest filing, from -$1.5 billion in the prior quarter.
• Over five years, Retained Earnings peaked at -$570.0 million in Q1 2022 and troughed at -$1.5 billion in Q1 2026.
• A 5-year average of -$1.0 billion and a median of -$1.0 billion in 2024 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2024 and 2026: Retained Earnings sank 39.98% in 2024, then slipped 11.59% in 2026.
• A 5-year view of Retained Earnings shows it stood at -$727.1 million in 2022, then slipped by 27.73% to -$928.7 million in 2023, then plunged by 36.0% to -$1.3 billion in 2024, then fell by 17.52% to -$1.5 billion in 2025, then retreated by 2.05% to -$1.5 billion in 2026.
• Business Quant data shows PHAT's Retained Earnings at -$1.5 billion in Q1 2026, -$1.5 billion in Q4 2025, and -$1.5 billion in Q3 2025.